Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer. A total of 90 patients were randomly divided into two groups: group CF was treated with a combination of celecoxib and the folinic acid-fluorouracil-oxaliplatin (FOLFOX4) regimen; and group F was treated with the FOLFOX4 regimen alone. Immunohisto chemical analysis of tumour tissues for cyclooxygenase-2 (COX-2) protein was performed. With regard to short-term efficacy, the response and disease control rates were significantly greater in group CF than group F. A log-rank test showed that the 3-year survival rate was significantly greater in group CF than group F. It was concluded that the addition of celecoxib to the FOLFOX4 regimen increased the short-term efficacy and the 3-year survival rate, and improved the quality of life of patients with advanced colorectal cancer. The antitumour and chemo sensitizing effects of celecoxib appeared to be independent of COX-2.